A collagen binding assay: An additional method for von Willebrand factor activity in therapeutic concentrates

Thrombosis and Haemostasis

Volumn 88, Issue 5, 2002, Pages 871-872

  Neugebauer, B M ^a   Goy, C ^a   Seitz, R ^a  

^a PAUL EHRLICH INSTITUT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BLOOD CLOTTING FACTOR 8 CONCENTRATE; COLLAGEN; COLLAGEN TYPE 1; COLLAGEN TYPE 3; DESMOPRESSIN; RISTOCETIN; VON WILLEBRAND FACTOR; BLOOD CLOTTING FACTOR 8;

ASSAY; BINDING AFFINITY; BLOOD VESSEL INJURY; CLINICAL TRIAL; DIAGNOSTIC KIT; DRUG ACTIVITY; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG RESPONSE; HUMAN; LETTER; METHODOLOGY; MOLECULAR WEIGHT; PRIORITY JOURNAL; THROMBOCYTE ADHESION; VON WILLEBRAND DISEASE; COMPARATIVE STUDY; METABOLISM; PROTEIN BINDING; REPRODUCIBILITY; TECHNIQUE;

COLLAGEN; FACTOR VIII; HUMANS; METHODS; PROTEIN BINDING; REPRODUCIBILITY OF RESULTS; VON WILLEBRAND FACTOR;

EID: 0036853012     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1613316     Document Type: Letter

References (11)

1. Favaloro EJ. Collagen binding assay for von Willebrand factor (vWF:CBA): Detection of von Willebrand disease (vWD), and discrimination of vWD subtypes, depends on the collagen source. Thromb Haemost 2000; 83: 127-35.
2. Siekmann J, Turecek PL, Schwarz HP. The determination of von Willebrand factor activity by collagen binding assay. Haemophilia 1998; 4 (Suppl. 3): 15-24.
3. Brown JE, Bosak JO. An ELISA for the binding of von Willebrand antigen to collagen. Thromb Res 1986; 43: 303-11.
4. Thomas KB, Choong SC, Jessat U, et al. Platelet von Willebrand factor-collagen binding activity and ristocetin cofactor activity: a comparison of methods able to differentiate von Willebrand disease type I and II (preliminary results). In: Scharrer I, Schramm W, eds. 24. Hämophilie Symposium Hamburg 1993, Berlin, Heidelberg: Springer-Verlag 1994; 234-42.
5. Neugebauer BM, Goy C, Budek I, Seitz R. Comparison of two von Willebrand Factor Collagen Binding Assays with Different Binding affinities for Low, Medium and High Multimers of von Willebrand Factor. Sem Thromb Hemost 2002; 28: 139-47.
6. Fischer BE, Kramer G, Mitterer A et al. Effect of multimerization of human and recombinant von Willebrand factor on platelet aggregation, binding to collagen and binding of coagulation factor VIII. Thrombosis Research 1996; 84: 55-66.
7. Metzner HJ, Hermentin P, Cuesta-Linker T, et al. Characterisation of factor VIII/von Willebrand factor concentrates using a modified method of von Willebrand multimer analysis. Haemophilia 1998; 4 (Suppl. 3): 25-32.
8. Mannucci P.M. Treatment of von Willebrand disease. Thromb Haemostas 2001; 86: 146-53.
9. Ewenstein BM. Use of ristocetin cofactor activity in the management of von Willebrand disease. Haemophilia 2001; 7 (Suppl. 1): 10-5.
10. Neugebauer BM, Volkers P, Seitz R. von Willebrand Factor Potency Determination by Collagen Binding Assay. A Collaborative Study for the Establishment of a European Pharmacopoeia Method. PharmEuropa 2000; 14.2: 315-27.
11. Assay of human von Willebrand factor. PharmEuropa 2002; 14.2: 377-8.